Negative Syndrome

Related by string. * Negatives . negatives . NEGATIVE . NEGATIVES . nega tive : Rating Watch Negative . Negative Rating Outlook . Negative Outlook reflects . O Negative . estrogen receptor negative / syndromes . Syndromes . SYNDROME . syndrome : Severe Acute Respiratory Syndrome . Acquired Immune Deficiency Syndrome . Acquired Immune Deficiency Syndromes . chronic fatigue syndrome * *

Related by context. All words. (Click for frequent words.) 87 Scale PANSS 82 PANSS 80 Montgomery Asberg Depression 78 Rating Scale MADRS 76 Brief Psychiatric 74 Montgomery Åsberg Depression 74 YMRS 74 Alzheimer Disease Assessment 73 Negative Symptoms 72 Global Impression 71 PANSS total 70 MADRS 70 Global Impression CGI 70 ADHD Rating Scale 70 Scale cognitive subscale 69 Unified Parkinson Disease 69 ADHD RS 69 Psoriasis Area 69 ADAS Cog 69 ADCS CGIC 68 State Examination MMSE 68 MADRS score 68 nasal symptom 68 ADAS cog 68 CNS LS 68 Expanded Disability Status 67 HDRS 67 symptom severity 67 PANSS scores 67 HAM D# 67 HAQ DI 67 Index CDAI 67 IBDQ 67 IRLS 67 HAM D 66 HAMD 66 Scale EDSS 66 Neuropsychiatric Inventory 66 UPDRS 66 subscales 66 Visual Analog Scale 65 Crohn Disease Activity 65 PANSS Positive 65 subscale scores 65 CDAI score 65 Primary endpoints 65 UPDRS motor 65 Rating Scale UPDRS 65 Severity Index PASI 65 Health Assessment Questionnaire 65 Pain Intensity 65 DAS# [002] 64 International Prostate Symptom 64 Rating Scale BPRS 64 Rating Scale 64 Neuropsychiatric Inventory NPI 64 Clinician Administered PTSD 64 mg TID 64 TNSS 64 WOMAC pain 64 Score IPSS 64 NIH CPSI 64 Scale Cognitive Subscale 64 APACHE II 64 QIDS SR 63 Severity MSCS score 63 mTSS 63 Mean Symptom Complex 63 IPSS 63 liver histology 63 Secondary endpoints included 63 Brief Pain 63 HOMA IR 63 exploratory endpoints 63 fasting plasma glucose 63 Inventory BPI 63 Negative Symptom Scale PANSS 63 Geriatric Depression 63 Hamilton Rating Scale 63 Hamilton Anxiety Scale 63 WOMAC TM 62 retinal thickness 62 Mania Rating Scale 62 Negative Symptom Scale 62 Visual Analogue Scale VAS 62 Distress Scale 62 Disease Activity 62 posttest 62 secondary efficacy endpoint 62 QoL 62 achieved statistical significance 62 Beck Anxiety Inventory 62 extrapyramidal symptoms 62 subscores 62 depressive symptom 61 Fibromyalgia Impact Questionnaire 61 IRLS score 61 total cholesterol LDL 61 Secondary endpoints 61 WOMAC 61 EQ 5D 61 Physical Component 61 -#.# mg dL [002] 61 secondary endpoint 61 Depression Rating Scale 61 CDAI 61 MoxDuo TM IR 61 Visual Analog 61 Demonstrated Significant 61 Index CDAI score 61 SGRQ 61 subscore 61 desvenlafaxine succinate 61 Global Impression Severity 61 ADCS ADL 61 fasting insulin 61 adjunctive placebo 61 moderate renal impairment 61 rosuvastatin #mg 61 Functioning GAF 61 BPRS 61 Edinburgh Postnatal Depression 61 serum phosphorous 61 cognitive affective 61 DAS# scores 60 GERD symptom 60 euthymic patients 60 mg BID dose 60 elevated ALT 60 trough FEV1 60 BMI z 60 ARB telmisartan 60 clinically meaningful improvement 60 serum potassium 60 Y BOCS 60 ASIA Impairment 60 quetiapine XR 60 Main Outcome Measures 60 Secondary efficacy endpoints 60 HADS 60 alanine aminotransferase ALT 60 Ocular Surface Disease 60 Mental Component 60 Desvenlafaxine Succinate 60 fasting plasma glucose FPG 60 MMSE score 60 -#.# mg dL [001] 60 Score DAS# 60 virologic response 60 virological response 60 Score DAS 60 convergent validity 60 DAS# CRP 59 oxycodone CR 59 Pharmacokinetic parameters 59 LOCF 59 secondary efficacy endpoints 59 mcg QD 59 % Confidence Interval 59 prespecified secondary 59 lopinavir r arm 59 Treatment Diabetic Retinopathy 59 Pain Rating Scale 59 Rosenberg Self Esteem 59 aspartate aminotransferase AST 59 PASI scores 59 NIHSS 59 glycated hemoglobin HbA1c 59 Depression Inventory 59 Interrater reliability 59 Cystic Fibrosis Questionnaire Revised 59 interrater reliability 59 HbA1c levels 59 ACR# response 59 demonstrated statistically significant 59 ANOVA 59 serum urate 59 LVEF 59 CANCIDAS 59 emotional lability 59 mRS 59 HRQL 59 antipsychotic efficacy 59 Abnormal Involuntary Movement 59 SELENA SLEDAI 59 State Trait Anxiety 59 calculated creatinine clearance 59 Cronbach alpha 59 abacavir lamivudine 59 PCWP 59 apolipoprotein B 59 Oral Fingolimod 59 Cockcroft Gault 59 pain subscale 59 Physical Function 58 8mg/kg 58 #mg/day [001] 58 sUA 58 EDSS score 58 Symptom severity 58 DLQI 58 annualized relapse 58 ziprasidone 58 hemoglobin A1c HbA1c 58 CCyR 58 scores TNSS 58 divalproex 58 ACR# ACR# 58 INVEGA ® 58 lumbar spine BMD 58 Depressive Symptoms 58 ACTEMRA TM 58 plus methotrexate 58 budesonide pMDI 58 Visual acuity 58 Sensitivity specificity 58 non menstrual pelvic 58 laboratory abnormalities 58 certolizumab 58 HRQOL 58 CrCl 58 PERMP 58 alanine aminotransferase 58 creatinine clearance 58 tolvaptan 58 glycosylated hemoglobin HbA1c 58 retest reliability 58 abdominal pain abdominal discomfort 58 divalproex sodium 58 #.#/#.# mmHg [001] 58 PSADT 58 Scale EDSS score 58 Solid Tumors criteria 58 affective psychosis 58 urinary N telopeptide 58 tipranavir r 58 placebo p 58 confirmed CCyR 58 risperidone 58 intima media thickness 58 Response Evaluation Criteria 58 mg RDEA# 58 bronchial hyperresponsiveness 58 Status Scale EDSS 58 solifenacin 58 undetectable HBV DNA 58 placebo fluoxetine 58 aspartate aminotransferase 58 EDEMA3 trial 58 log# copies mL 57 tapentadol ER 57 infliximab monotherapy 57 depressive symptomatology 57 4mg/kg 57 univariate 57 OGTT 57 RECIST Response Evaluation Criteria 57 Demonstrate Significant 57 Naive Patients 57 Epworth Sleepiness Scale 57 gadolinium enhancing lesions 57 R# #mg BID 57 HBeAg seroconversion 57 #mg BID [003] 57 Metastatic Renal Cell Carcinoma 57 aldosterone antagonist 57 morphometric vertebral fractures 57 urine albumin 57 citalopram 57 insulin detemir 57 mcg BID 57 glomerular filtration rate 57 D dimer 57 prospectively defined 57 subjective sleepiness 57 hemoglobin A1c levels 57 -#.# ± [002] 57 venlafaxine XR 57 #mg/day [002] 57 SSRI SNRI 57 BENICAR HCT 57 NYHA functional class 57 RLAI 57 mg QD 57 Secondary endpoints include 57 #mg dose [002] 57 REYATAZ r arm 57 6MWD 57 Scale CNS 57 nonfatal MI 57 Pearson correlation coefficient 57 x ULN 57 Cronbach 57 antidepressant efficacy 57 CIMZIA TM 57 baseline HbA1c 57 Score TOS 57 LEXIVA r 57 SSRI citalopram 57 Functional Assessment 57 tolterodine ER 57 Knodell necroinflammatory score 57 Thrombolysis 57 tiotropium 57 ETDRS 57 Dyspnea 57 subthreshold depression 57 Capacity FVC 57 symptomatic VTE 57 adjunctive ABILIFY 57 rheumatoid factor 57 Primary Endpoint 57 erythrocyte sedimentation rate 57 SELENA SLEDAI score 57 unfractionated heparin UFH 57 tirofiban 57 PSQI 57 BPH symptom 57 serum HBV DNA 57 APTIVUS r 57 concomitant medications 57 cytogenetic response 57 MMSE scores 57 plasma cortisol 57 composite endpoint 57 FACIT Fatigue 57 Mini Mental 57 EDSS 57 Tumor Response 57 generalized estimating 57 ritonavir boosted 57 Low Density Lipoprotein Cholesterol 57 glycosylated hemoglobin levels 57 Pegasys ® 57 NIS LL 57 endoscopic remission 57 clinically meaningful reductions 57 ATACAND 57 demonstrated clinically meaningful 57 apnea hypopnea index 56 Wilcoxon rank sum 56 achieved ACR# 56 univariate analysis 56 Subscale 56 Cholinesterase Inhibitors 56 symptomatology 56 SGOT 56 unpaired t 56 pramipexole 56 metabolic parameters 56 HRQoL 56 lymphopenia 56 quetiapine 56 HbA 1c 56 atheroma volume 56 Oswestry Disability Index 56 serum cortisol 56 mucosal healing 56 serum sodium 56 urate lowering therapy 56 UACR 56 P = .# 56 STRIDE PD 56 CIMZIA TM certolizumab pegol 56 binary restenosis 56 Left Ventricular Ejection Fraction 56 baseline A1C 56 PEG IFN 56 â ‰ ¥ 56 risperidone Risperdal 56 rhinoconjunctivitis 56 IIEF 56 placebo p = 56 HBeAg 56 intraobserver 56 -#.# log# 56 IU ml 56 paliperidone ER 56 mEq L 56 rimonabant #mg 56 Wechsler Adult 56 Repeatable Battery 56 Tolerability 56 Likert scale 56 multivariate Cox 56 active comparator 56 IKDC 56 biopsy Gleason 56 CI -#.# 56 Relapsing Multiple Sclerosis 56 carotid intima media 56 secondary endpoints 56 Depressive symptoms 56 Symptom Checklist 56 Wechsler Memory 56 p = .# [002] 56 baseline PASI 56 primary hypercholesterolemia 56 MCyR 56 -#.# log# copies mL 56 Numeric Rating Scale 56 mg BID 56 PHQ 9 56 amisulpride 56 nonsignificant 56 methotrexate monotherapy 56 plasma HCV RNA 56 Tiotropium 56 intima media thickness IMT 56 C Reactive Protein 56 Endocrine Therapy 56 glycosylated hemoglobin 56 eplerenone 56 covariate 56 Pharmacokinetics PK 56 alteplase 56 Non inferiority 56 sustained virologic response 56 postintervention 56 postdose 56 transaminases 56 irbesartan 56 HBsAg 56 Glasgow Coma Scale 56 oral glucose tolerance 56 somatic symptoms 56 blood Phe 56 lamotrigine 56 iloprost 56 glycated hemoglobin levels 56 lipid parameters 56 Platelet counts 56 Hemoglobin A1c 56 urinary calcium excretion 56 aripiprazole 56 receiving golimumab 56 statistically significant improvement 56 baseline FEV 56 semiquantitative 56 hepatic enzyme 56 PREZISTA r arm 56 μg kg 56 IFN α 56 platelet reactivity 56 Pred Forte 56 interobserver 56 zonisamide SR 56 atherogenic dyslipidemia 56 fructosamine 55 oral antidiabetic medication 55 glycated hemoglobin 55 Change PGIC 55 mg kg dose 55 TMC# r 55 somatostatin analog 55 F FDG PET 55 lipoprotein Lp 55 UPDRS Part III 55 logistic regression 55 CD4 CD8 55 triiodothyronine 55 SKAMP D 55 Aripiprazole 55 OADs 55 QTc 55 teriflunomide 55 depressive symptoms 55 HBV DNA levels 55 psychosocial functioning 55 EBMT criteria 55 Likert pain 55 Wechsler Intelligence 55 CIMZIA ™ 55 lispro 55 hip BMD 55 QTc prolongation 55 clinically meaningful improvements 55 sensitivity specificity 55 ANCOVA 55 PEGINTRON TM 55 Ejection Fraction 55 FOLFOX6 55 hsCRP 55 SF #v# 55 FDG uptake 55 lymphocyte count 55 CORE OM 55 plasma leptin 55 HbA 1c levels 55 pharmacodynamic parameters 55 hemoglobin A1C 55 dapagliflozin plus 55 subtests 55 Orthostatic Hypotension 55 Sustained virologic response 55 Cystatin C 55 Main Outcome Measure 55 estimated glomerular filtration 55 Glycemic Control 55 serum testosterone 55 serum phosphorus 55 BYSTOLIC 55 spontaneous bowel movements 55 response CCyR 55 weekly CSBMs 55 Chronic Illness Therapy 55 Peginterferon Alfa 2a 55 left ventricular diastolic 55 Functional Outcomes 55 TEAEs 55 Depression Scale 55 haematologic 55 HCV RNA 55 MMSE 55 Index FSFI 55 plus MTX 55 preoperatively 55 urinary albumin 55 intraclass correlation coefficient 55 p = #.# [002] 55 mg qd 55 sweat chloride 55 coronary stenosis 55 Symptom Score 55 IV bolus 55 ACR Pedi 55 prospectively stratified 55 PegIFN RBV 55 albumin excretion rate 55 fosamprenavir 55 serum HCV RNA 55 glimepiride 55 NIHSS score 55 test OGTT 55 galiximab 55 EDSS scores 55 nausea photophobia 55 guanfacine extended release 55 antibody titer 55 XIENCE V PROMUS Stent 55 Apidra ® 55 quetiapine risperidone 55 ALS Functional 55 plasma pharmacokinetics 55 HbA1c 55 serologically active patients 55 internalizing behaviors 55 paricalcitol 55 aminotransferases 55 euthymic 55 p = #.# [003] 55 events MACE 55 Ishak fibrosis score 55 Kruskal Wallis test 55 pulmonary capillary wedge 55 complete cytogenetic 55 Pioglitazone 55 adenoma recurrence 55 -#.# mmHg 55 Visual Analogue Scale 55 Treatment Outcome 55 bone marrow reticulin deposition 55 HER2 expression 55 psychometric properties 55 Kaplan Meier analysis 55 #mg dose [003] 55 HbA1C 55 confidence intervals CIs 55 olanzapine 55 Impressions Improvement 55 corticosteroid dose 55 hematological parameters 55 prespecified 55 serum BDNF 55 Cardiac Resynchronization 55 odds ratios ORs 55 prolactin elevation 54 5 Fluorouracil 54 oral levofloxacin 54 Solid Tumors 54 LEXIVA 54 IU mL 54 Monotherapy 54 Placebo Controlled Trial 54 Mg Uk 54 mU liter 54 FOLFOX4 54 HBeAg negative patients 54 D Dimer 54 point Likert scale 54 imipramine 54 ug kg 54 Description Enhance 54 specific antigen PSA 54 aminotransferase levels 54 BENICAR 54 peginterferon alfa 2a 54 Cardiac Function 54 abciximab 54 immunostaining 54 events AEs 54 β blocker 54 oxcarbazepine 54 myocardial perfusion 54 Non Responders 54 serum prostate 54 hematologic parameters 54 NCQA accreditation surveys 54 ribavirin RBV 54 ABC/3TC 54 -5 -6 54 polysomnography PSG 54 State Exam MMSE 54 serum IGF 54 somatic symptom 54 chlorambucil 54 moderate hepatic impairment 54 blood Phe levels 54 Statistically Significant 54 Hb A1C 54 serum bilirubin 54 Capsules CII 54 BPRS PSS 54 Peginterferon 54 transaminase elevations 54 prednisone prednisolone plus 54 Acute Physiology 54 PSA nadir 54 Depressive Symptomatology 54 dyspnoea 54 serum creatinine 54 inotropic 54 FOLFIRI 54 lumbar spine bone 54 aminotransferase ALT 54 proteinuria 54 GAMMAGARD 54 subsyndromal 54 Well Tolerated 54 adefovir treated 54 neutrophil counts 54 partial remissions 54 postprocedure 54 serum triglycerides 54 Chronic Hepatitis C 54 ezetimibe simvastatin 54 serum leptin 54 hypoglycemic events 54 Depression Inventory BDI 54 adenotonsillectomy 54 Teriflunomide 54 HIV RNA 54 infarct size 54 Seattle Angina Questionnaire 54 Refractory Hodgkin Lymphoma 54 #q# deletion syndrome 54 CFQ R 54 CPAP adherence 54 dysthymia 54 TIMI 54 AST ALT 54 posttreatment 54 tapentadol IR 54 LANTUS R 54 pharmacodynamic PD 54 serum aminotransferase levels 54 serum PSA 54 variance ANOVA 54 dactylitis 54 NLX P# 54 Forced Vital 54 Apolipoprotein B 54 T2DM 54 neurocognitive function 54 phonophobia 54 Predictive Value 54 lopinavir r 54 mcg Albuferon 54 nerve conduction velocity 54 function subscale 54 hemodynamic parameters 54 hemagglutination inhibition HAI 54 Alzheimer Disease Cooperative 54 primary efficacy endpoint 54 diameter stenosis 54 lispro alone 54 Likert 54 poststroke 54 Symptom Severity 54 azilsartan medoxomil 54 CONCERTA ® 54 alfa 2a 54 treat NNT 54 FOLPI 54 Pharmacodynamic 54 SVR# 54 NPH insulin 54 Castration Resistant Prostate Cancer 54 fasting blood glucose 54 Pearson correlation coefficients 54 colesevelam HCl 54 Persistent Sleep 54 creatinine clearance CrCl 54 Ambulatory Blood Pressure 54 Key secondary endpoints 54 log# IU mL 54 Prognostic Value 54 hypophosphatemia 54 neuroleptic 54 metabolite concentrations 54 Folfox 54 pharmacokinetic parameters 54 primary efficacy endpoints 54 MSLT 54 NWEA MAP 54 Study ETDRS 54 logistic regression analysis 54 AUA Symptom Score 54 racemic albuterol 54 Severity Index 54 clomipramine 54 adalimumab 54 Anti Tumor Activity 54 aminotransferase elevations greater 54 MARINOL R 54 System IPSS 54 STRATEGY FOR AN OPEN 54 hyperactivity impulsivity 54 #.#ng/ml 54 PSA kinetics 54 NATRECOR R 54 log# reduction 54 erection hardness 54 pharmacodynamic 54 Timed Walk 54 Skin sterol 54 icatibant 54 unresectable HCC 54 plasma folate 54 complete cytogenetic response 54 carotid IMT 54 multivariate logistic regression 54 Neuropsychological Status 54 creatinine ratio 54 dizziness nausea diarrhea 54 Echocardiographic 54 See CLINICAL PHARMACOLOGY 54 pyrexia mucositis sepsis febrile 54 Pharmacokinetic 54 Disease Severity 54 Viral Load 54 periprocedural 54 systolic BP 54 statistically significant p 54 dose proportionality 54 salmeterol fluticasone 54 SGPT 54 mm Hg diastolic 54 ACR# [002] 54 HDL Cholesterol 53 Pooled Analysis 53 linaclotide treated 53 Vildagliptin 53 Randomized Double blind 53 Histologic 53 RE LY ® 53 Long Term Efficacy 53 SPIRIT FIRST 53 Outcomes Study 53 Epidemiologic Studies Depression 53 Myocardial Infarction Study 53 Acute Ischemic Stroke 53 thyroglobulin 53 Zometa hazard 53 budesonide formoterol 53 glomerular filtration 53 Decitabine 53 copies mL 53 overnight polysomnography 53 multiple logistic regression 53 Tasigna prolongs 53 Endothelial function 53 Randomized Double Blind 53 CIBIC plus 53 unfractionated heparin 53 Free Survival PFS 53 CSBMs 53 d dimer 53 A1C levels 53 cEVR 53 dose dependently 53 premorbid 53 rilonacept 53 Index HAQ DI 53 CK # plasma 53 protein excretion 53 p = NS 53 Partial Response 53 Showed Significant 53 Rating Scale IRLS 53 Postoperative 53 undetectable HCV RNA 53 #mg doses [002] 53 % CI #.#-#.# [007] 53 incontinence episodes 53 Lantus ® 53 cilostazol 53 Sterilization Supplies Markets Independently 53 MBq 53 evaluable subjects 53 plus OBT 53 FEV1 53 placebo PBO 53 intraocular pressure IOP 53 mg ustekinumab 53 intraclass correlation coefficients 53 ULORIC 53 Treatment Naive Patients 53 low dose cytarabine 53 Anxiety Depression 53 mg tid 53 pharmacokinetics PK 53 Meets Primary Endpoint 53 Assessment Scale 53 psychopathological symptoms 53 hemoglobin Hb 53 atorvastatin #mg 53 ALT AST 53 iPTH 53 Nephrol Dial Transplant 53 TDF FTC 53 CorVue ™ 53 echocardiographic parameters 53 urinary cortisol 53 median PFS 53 conditional logistic regression 53 CRp 53 psychosocial variables 53 Recurrence Score 53 genotypic resistance 53 ARCOXIA 53 metformin IR 53 mcg albinterferon alfa 2b 53 Prognostic 53 methotrexate MTX 53 virologic responses 53 IIIa inhibitor 53 pharmacodynamic effects 53 spirometric 53 Natalizumab 53 salmeterol inhalation powder 53 lactate dehydrogenase LDH 53 receiving VICTRELIS 53 HCV antibody 53 NAbs 53 Versus Placebo 53 fluticasone salmeterol 53 multivariable analysis 53 pretest probability 53 SUVmax 53 Subgroup analysis 53 death reinfarction 53 pulmonary exacerbations 53 biochemical recurrence 53 ertapenem 53 Bonferroni correction 53 Subgroup Analysis 53 nicardipine 53 Nesiritide 53 sertraline 53 Descriptive statistics 53 serum CRP 53 umol L 53 oral allopurinol 53 febrile neutropenia 53 metformin monotherapy 53 ACE inhibitor ramipril 53 Anticancer Activity 53 #F FDG PET 53 postoperative complication 53 moderate hepatic insufficiency 53 Hemoglobin A1c HbA1c 53 ALSFRS R 53 HCV SPRINT 53 mL/min/#.# m 2 53 3mg/kg 53 Stroke Scale NIHSS 53 Peg IFN 53 inattention hyperactivity 53 preoperative PSA 53 Generalized Anxiety Disorder 53 affective disorders 53 analgesic efficacy 53 eNO 53 Newly Diagnosed Multiple Myeloma 53 hypomagnesemia 53 Adalimumab 53 antiviral efficacy 53 Patients Receiving 53 PEGylated anti 53 salivary cortisol 53 #.#/#.# mm Hg [003] 53 ropivacaine 53 albumin excretion 53 ACR# responses 53 achieved PASI 53 antihypertensive medications 53 lymphovascular invasion 53 Elderly Patients 53 lymphocytosis 53 Efficacy 53 Relapsing Remitting Multiple Sclerosis 53 mild renal insufficiency 53 baseline serum creatinine 53 RAPAFLO R 53 WOMAC scores 53 dose atorvastatin 53 troponin T 53 Maturity Model Integration 53 Durezol 53 steroid dexamethasone 53 weekly subcutaneous injections 53 Left Ventricular 53 treatment emergent adverse 53 Index WOMAC 53 Statin Therapy 53 KOOS 53 Kidney Function 53 A1c levels 53 venlafaxine Effexor 53 mediated dilation 53 exhaled nitric oxide 53 + PH# 53 plasma triglycerides 53 benazepril 53 Dose Escalation 53 mRNA expression 53 imipramine Tofranil 53 pharmacokinetic PK profile 53 akathisia 53 Virologic 53 undetectable viral 53 CYP#A# substrate 53 EMBLEM TM 53 erlotinib Tarceva ® 53 avosentan 53 progesterone receptor PR 53 statistically significant reduction 53 detectable HCV RNA 53 clinical meaningfulness 53 mcg kg 53 Natural Catastrophe Stress 53 hepatic enzymes 53 urinary calcium 53 BILAG 53 Rate ORR 53 Follicular Lymphoma 53 ug dose 53 p = .# [001] 53 Median PFS 53 highly emetogenic 52 #mg QD [002] 52 Ziprasidone 52 statistically significant efficacy 52 COMBIVIR 52 sotalol 52 Bosentan 52 comparator arm 52 comorbid 52 interobserver reliability 52 DOXIL 52 psychophysiological 52 axillary lymph node 52 evaluating tivozanib 52 vitreous haze 52 immunohistochemical 52 #mg BID [001] 52 NNT = 52 rotigotine 52 patients evaluable 52 anti JCV antibodies 52 Child Behavior Checklist 52 LDL HDL 52 Total Nasal Symptom 52 comorbid anxiety 52 sustained virological response 52 microgram kg 52 akinesia 52 Clinical Outcome 52 oral FTY# 52 inotropic agents 52 zolmitriptan 52 Solid Tumors RECIST 52 leukopenia 52 p = #.# [004] 52 0 document.write 52 macroalbuminuria 52 Platelet Function 52 Ranolazine

Back to home page